Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005516 | 0.90 | PTGS2 (0.33) | HSP90AA1PTGS2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL936383 | 0.87 | GABRA1 (0.42) | ARGABRA1GABRB2KDRPTGS2 | |
| SCHEMBL936384 | 0.85 | AR (0.34) | HSP90AA1ARKDRTP53PIM1 | |
| SCHEMBL1003882 | 0.81 | HSP90AA1 (0.47) | HSP90AA1ARGABRA1GABRB2PTGS2 | |
| SCHEMBL1005514 | 0.79 | — | — | |
| SCHEMBL956042 | 0.78 | HSP90AA1 (0.45) | HSP90AA1ARPTGS2CYP1A2CYP3A4 | |
| SCHEMBL12943752 | 0.77 | HSP90AA1 (0.43) | HSP90AA1ARGABRA1GABRB2CYP1A2 | |
| SCHEMBL18890281 | 0.75 | HSP90AA1 (0.56) | HSP90AA1GABRA1GABRB2PTGS2CYP1A2 | |
| SCHEMBL989648 | 0.72 | AR (0.46) | ARKDRTP53CYP1A2CYP3A4 | |
| SCHEMBL12950642 | 0.68 | AR (0.46) | HSP90AA1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158733-B2 | Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands | EQUISTAR CHEMICALS, LP (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158733-B2 | Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands | EQUISTAR CHEMICALS, LP (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158733-B2 | Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands | EQUISTAR CHEMICALS, LP (US) | 2012-04-17 | — | — | US | disclosed |
| US-8153544-B2 | Method for preparing non-metallocene catalysts | EQUISTAR CHEMICALS, LP (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153544-B2 | Method for preparing non-metallocene catalysts | EQUISTAR CHEMICALS, LP (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153544-B2 | Method for preparing non-metallocene catalysts | EQUISTAR CHEMICALS, LP (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110021344-A1 | Method for preparing non-metallocene ligands | EQUISTAR CHEMICALS, LP | 2011-01-27 | — | — | US | disclosed |
| US-20110021344-A1 | Method for preparing non-metallocene ligands | EQUISTAR CHEMICALS, LP | 2011-01-27 | — | — | US | disclosed |
| US-20110021344-A1 | Method for preparing non-metallocene ligands | EQUISTAR CHEMICALS, LP | 2011-01-27 | — | — | US | disclosed |
| US-20110021727-A1 | Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands | EQUISTAR CHEMICALS, LP | 2011-01-27 | — | — | US | disclosed |
| US-20110021727-A1 | Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands | EQUISTAR CHEMICALS, LP | 2011-01-27 | — | — | US | disclosed |
| US-20110021727-A1 | Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands | EQUISTAR CHEMICALS, LP | 2011-01-27 | — | — | US | disclosed |
| WO-2011011040-A1 | CATALYSTS BASED ON 2-(2-ARYLOXY) QUINOLINE OR 2-(2-ARYLOXY) DIHYDROQUNIOLINE LIGANDS | EQUISTAR CHEMICALS, LP (US) | 2011-01-27 | — | — | WO | disclosed |